A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer

To characterize programmed cell death ligand-1 (PD-L1) expression in relation to survival and gene mutation status in patients with advanced NSCLC. The study also explored the influence of tumor mutational burden (TMB) on PD-L1 expression and patient characteristics. Adult patients with histological...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2019-01, Vol.11, p.9469-9481
Main Authors: Schabath, Matthew B, Dalvi, Tapashi B, Dai, Hongyue A, Crim, Alan L, Midha, Anita, Shire, Norah, Gimbrone, Nicholas T, Walker, Jill, Greenawalt, Danielle M, Lawrence, David, Rigas, James R, Brody, Robert, Potter, Danielle, Kumar, Naveen S, Huntsman, Shane A, Gray, Jhanelle E
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Cancer therapies
Cell death
Chemotherapy
Deoxyribonucleic acid
DNA
Epidemiology
FDA approval
Genomes
Immunotherapy
Kinases
Ligands
Lung cancer
Medical prognosis
Metastasis
Mutation
non-small cell lung cancer
Oncology
Original Research
patient outcomes
Patients
prognostic biomarker
Research centers
Survival analysis
tumor mutational burden
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To characterize programmed cell death ligand-1 (PD-L1) expression in relation to survival and gene mutation status in patients with advanced NSCLC. The study also explored the influence of tumor mutational burden (TMB) on PD-L1 expression and patient characteristics. Adult patients with histologically or cytologically documented Stage IIIB/Stage IV/recurrent/progressive NSCLC, Eastern Cooperative Oncology Group performance status 0 to 3, and >2 lines of prior systemic treatment regimens were included in this retrospective analysis. Patients were treated from 1997 to 2015 at H. Lee Moffitt Cancer Center and Research Institute, Tampa, or at 7 community centers across the United States. PD-L1 expression level was determined using the VENTANA PD-L1 (SP263) Assay. and mutation status and rearrangements were determined by targeted DNA sequencing; these were obtained from clinical records where targeted DNA sequencing was not performed. TMB was calculated as the total number of somatic mutations per sample. From a total of 136 patients included in the study, 23.5% had tumors with high PD-L1 expression (≥25%). There were no significant differences in patient characteristics, overall survival (OS), and progression-free survival (PFS) between patients with high PD-L1 expression (median OS: 39.5 months; median PFS: 15.8 months) vs low PD-L1 expression (
ISSN:1179-1322
1179-1322
DOI:10.2147/cmar.s218635